CAS 448904-47-0: Butanedioic acid, compd. with4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol (1:1)

WY 45233 Succinate is a pharmacological compound, specifically an experimental hypolipidemic agent. It is derived from synthetic medicinal chemistry efforts aimed at modulating lipid profiles in the body. The compound operates by activating peroxisome proliferator-activated receptors (PPARs), which play a crucial role in the regulation of lipid metabolism and adipogenesis. Through this mechanism, WY 45233 Succinate enhances the oxidation of fatty acids and modulates the expression of genes involved in lipid transport and homeostasis. The primary application of WY 45233 Succinate is in the management of hyperlipidemia and associated disorders, such as cardiovascular diseases. By effectively reducing cholesterol levels and improving lipid profiles, it offers potential as a therapeutic agent for reducing the risk of atherosclerosis and related cardiovascular conditions. Research is ongoing to fully elucidate its efficacy and safety profile for potential clinical use.